Dry Eye and Rheumatoid Arthritis

From a western clinical standpoint, the relationship between dry eye disease (DED) and rheumatoid arthritis (RA) is best understood through shared autoimmune biology. In RA, dysregulated B‑ and T‑cell activity produces autoantibodies and pro‑inflammatory cytokines (TNF‑α, IL‑1, IL‑6) that drive synovitis and extra‑articular manifestations. When exocrine glands are targeted—most notably the lacrimal glands—aqueous tear secretion falls, and ocular surfaces become inflamed, a pattern overlapping with secondary Sjögren’s syndrome. Epidemiologic studies consistently show a higher burden of DED among people with RA, particularly women, older adults, those with longer disease duration, and seropositive individuals. Meibomian gland dysfunction often coexists, further destabilizing the tear film. Diagnosis integrates symptoms with office‑based testing: Schirmer’s assesses tear production, tear break‑up time evaluates stability, and fluorescein/lissamine green staining highlights epithelial damage. Tear osmolarity and MMP‑9 can index inflammation. Hallmarks that suggest autoimmune‑related dry eye include pronounced aqueous deficiency, filamentary keratitis, and concomitant xerostomia or salivary gland enlargement. Red flags—such as severe pain, photophobia, decreased vision, scleritis, or peripheral ulcerative keratitis—warrant urgent ophthalmology assessment and frequently systemic immunosuppression. Management is two‑pronged. Local therapies (lubricants, topical anti‑inflammatories like cyclosporine or lifitegrast, punctal occlusion, autologous serum tears, scleral lenses) target tear film restoration and ocular surface healing. Systemic control of RA with DMARDs and biologics can reduce inflammatory spillover to the eye, though established glandular damage may limit tear recovery. Clinicians should remain vigilant for medication‑related ocular effects—hydroxychloroquine retinopathy requires periodic screening, and corticosteroids can cause cataract and glaucoma. Lifestyle measures such as smoking cessation and an anti‑inflammatory dietary pattern may support both joint and ocular health. Close coordination between rheumatology and ophthalmology optimizes outcomes and protects vision.

Traditional frameworks view the eye–joint connection as expressions of a systemic imbalance. In TCM, chronic joint pain and swelling in RA map to Bi syndrome—an obstruction by wind, dampness, and heat—while eye dryness reflects Liver–Kidney Yin deficiency with internal heat consuming fluids. Treatment aims to clear heat and nourish Yin, thereby replenishing tears. Acupuncture is applied both locally and systemically to modulate pain and support lacrimal function; small trials suggest improvements in symptoms and tear stability, though research methods vary. Herbal strategies (e.g., formulas that enrich Liver–Kidney Yin and soothe ocular discomfort) are tailored to pattern differentiation and are intended to complement, not replace, conventional care. Ayurveda conceptualizes RA‑like illness as Ama‑Vata, in which metabolic residues (ama) drive inflammation. Ocular dryness is linked to Vata/Pitta aggravation and depletion of ojas (vital essence). Therapies include dietary correction to strengthen digestion (agni), gentle cleansing, rasayana (rejuvenative) support, and localized eye‑soothing measures such as netra tarpana under specialist supervision. Mind–body practices—yoga, pranayama, meditation—as well as qigong or tai chi are used to reduce stress and systemic inflammatory tone, potentially easing both joint and ocular symptoms. From an integrative perspective, these approaches align with modern goals: lowering inflammation, improving comfort, and supporting adherence. While the evidentiary base is still emerging compared with pharmacologic trials, many interventions are low‑risk when guided by qualified practitioners and coordinated with rheumatology and ophthalmology care.